



ABN 53 075 582 740

ASX ANNOUNCEMENT

3 June 2011

BNC105 RENAL CANCER TRIAL TO BE PRESENTED AT ASCO

Bionomics Limited (ASX: BNO) (ADR: BMICY) will display a poster presentation outlining the BNC105 clinical trial in patients with progressive metastatic renal cancer at the annual American Society for Clinical Oncology (ASCO) meeting in Chicago, Illinois.

Dr Thomas E Hutson of the Baylor Sammons Cancer Center-Texas Oncology is lead author and also Principal Investigator of the trial, which is being conducted for Bionomics by the Hoosier Oncology Group. The presentation will be given during the Trials in Progress Poster Session 8am to 12pm Monday 6 June in McCormick Place Hall A.

On 1 April 2011 Bionomics announced the presentation of preclinical data supporting the current trial in patients with renal cancer at the American Association for Cancer Research (AACR). The data demonstrated the potent vascular disrupting effects of BNC105 in two mouse models of renal cancer, including a model in which the cancer spreads to the lungs. BNC105 induced tumour blood vessel shutdown in both the primary tumour and the secondary lung cancer.

Sutent, a tyrosine kinase inhibitor (TKI), is used in first line therapy of renal cancer. BNC105 activity was shown to be comparable with the blockbuster drug Sutent which had worldwide sales of US\$1.066 billion in 2010.

Treatment options remain limited in progressive metastatic renal cell cancer for patients who no longer respond to TKI treatments such as Sutent. The BNC105 trial is being conducted in patients who have failed TKI therapy and are also being treated with Afinitor, an mTOR inhibitor.

Dr Thomas E Hutson commented "The mechanism of action of BNC105 provides an innovative approach to the treatment of solid tumours including metastatic renal carcinoma, by attacking established tumour vasculature. It is particularly exciting to be conducting a trial which has the potential of creating a new paradigm for the treatment of renal cancer."

"It makes sense that the combination of BNC105 with an agent active against mTOR would cut off a tumour "survival" response and improve clinical outcome. This clinical trial builds on our experience in the treatment of metastatic renal cancer with mTOR inhibitors and our preclinical data," he added.

Renal cell carcinoma accounts for approximately 85 per cent of kidney cancers, with kidney cancer accounting for 2-3 per cent of human malignancies. The incidence of renal cell cancer has been rising steadily. Every year approximately 200,000 cases are diagnosed worldwide, with 55,000 people diagnosed in the US. The five year survival rate for patients with metastatic disease is less than 2 per cent.

The posters can be found on the Bionomics website www.bionomics.com.au

Enquiries:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210 which has recently completed Phase Ib clinical trials. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNC105 or BNC210, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.